Global Epidemiology of Antimicrobial Resistance among Community-Acquired and Nosocomial Pathogens: A Five-Year Summary from the SENTRY Antimicrobial Surveillance Program (1997-2001)

ABSTRACT

Resistance to antimicrobial agents among clinically important pathogens in the community and hospital settings has compromised therapy and requires constant monitoring of emerging patterns. Although local information indexed by hospital service or ward remains preferred, the initiation of several comprehensive surveillance programs (SENTRY Antimicrobial Surveillance Program, MYSTIC Programme, ICARE, EARSS, etc.) offers quality susceptibility testing results to guide empirical treatment regimens. Enterococci and staphylococci with novel resistance mechanisms to glycopeptides (vancomycin, teicoplanin) require greater use of quinupristin/dalfopristin and linezolid. For streptococci, recent modifications of laboratory interpretive criteria for cefotaxime, ceftriaxone, and cefepime indicates that coverage remains at ≥ 95%. Extended-spectrum beta-lactamases in Enterobacteriaceae and multidrug resistance in Acinetobacter spp. and Pseudomonas aeruginosa most challenge our choices of effective agents for nosocomial infections. Few new drugs have surfaced for therapy of these gram-negative bacilli, and two- or three-agent combination regimens may be required with greater frequency, especially to cover the more prevalent resistances among both gram-positive cocci and gram-negative nonfermentative rods.

KEYWORDS

Resistance - antibiotics - nosocomial infections - empirical therapy - surveillance - SENTRY

REFERENCES

• 1 Jones R N. Resistance patterns among nosocomial pathogens, trends over the past few years.  Chest . 2001;  119 397S-404S
• 2 Weinstein R A. Nosocomial infection update.  Emerg Infect Dis . 1998;  4 416-420
• 3 Public Health Initiative Research Institute. Report from the Bacterial Antibiotic Resistance Group/Infectious Disease Center Washington, DC: U.S. Government Printing Office 1997
• 4 US Department of Health and Human Services. Addressing emerging infectious disease threats: A prevention strategy for the United States. Washington, DC:U.S. Government Printing Office; 1994
• 5 Impacts of antibiotic-resistant bacteria: thanks to penicillin, he will come home! Washington, DC: Office of Technology Assessment; 1995 Publication OTA-H-629 . 
• 6 Phelps C E. Bug-drug resistance: sometimes less is more.  Med Care . 1989;  27 194-203
• 7 Ibrahim E H, Sherman G, Ward W, Fraser V J, Kollef M H. The influence of inadequate antimicrobial treatment of blood stream infections on patient outcomes in the ICU setting.  Chest . 2000;  118 146-155
• 8 Kollef M H. Antimicrobial therapy of ventilator-associated pneumonia.  Chest . 1999;  115 8-11
• 9 Jones R N. The emergent needs for basic research, education, and surveillance of antimicrobial resistance: problems facing the report from the American Society for Microbiology Task Force on Antimicrobial Resistance.  Diagn Microbiol Infect Dis . 1996;  25 153-161
• 10 Bax R, Bywater R, Cornaglia G. Surveillance of antimicrobial resistance: what, how and whither?.  Clin Microbiol Infect . 2001;  7 316-325
• 11 Jones R N, Masterton R. Determining the value of antimicrobial surveillance programs.  Diagn Microbiol Infect Dis . 2001;  41 171-175
• 12 National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 5th ed. Approved standard M7- A5. Wayne, PA: NCCLS; 2000
• 13 National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. 12th informational supplement M100-S12. Wayne, PA: NCCLS; 2002
• 14 Turner P J, Greenhalgh J M, Edwards J R, McKellar J. The MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) Programme.  Int J Antimicrob Agents . 1999;  13 117-125
• 15 Global aspects of antimicrobial resistance among key bacterial pathogens: results from the 1997-1999 SENTRY Antimicrobial Surveillance Program.  Clin Infect Dis . 2001;  32(suppl 2) S81-S167
• 16 Pfaller M A, Jones R N, Doern G V. Bacterial pathogens isolated from patients with blood stream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada).  Antimicrob Agents Chemother . 1998;  42 1762-1770
• 17 Pfaller M A, Jones R N, Doern G V. Survey of blood stream infections due to gram-positive cocci: frequency of occurrence and antimicrobial susceptibility of isolates collected in 1997 in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program.  Diagn Microbiol Infect Dis . 1999;  33 283-297
• 18 Diekema D J, Pfaller M A, Jones R N, the SENTRY Participants Group. Trends in antimicrobial susceptibility of bacterial pathogens isolated from patients with blood stream infections in the USA, Canada and Latin America.  Int J Antimicrob Agents . 2000;  13 257-271
• 19 Moet G, Biedenbach D, Pfaller M, Jones R N. 2002; Occurrence of blood stream infection (BSI) pathogens and key resistances (R) from the SENTRY Antimicrobial Surveillance Program, a 5-year report [abstract C2-299]. In: Programs and Abstracts of the 42nd Interscience Congress of Antimicrobial Agents and Chemotherapy American Society for Microbiology, San Diego, CA
• 20 Diekema D J, Pfaller M A, Jones R N, and the SENTRY Participants Group. Age-related trends in pathogen frequency and antimicrobial susceptibility of blood stream isolates in North America: SENTRY Antimicrobial Surveillance Program, 1997-2000.  Int J Antimicrobial Agents . 2002;  20 412-418
• 21 Richards M J, Edwards J R, Culver D H, Gaynes R P. Nosocomial infections in pediatric intensive care units in the United States.  Pediatrics . 1999;  103 39-46
• 22 Villari P, Sarnataro C, Iacuzio L. Molecular epidemiology of Staphylococcus epidermidis in a neonatal intensive care unit over a three-year period.  J Clin Microbiol . 2000;  38 1740-1746
• 23 Mathai D, Lewis M T, Kugler K C, Pfaller M A, Jones R N, and the SENTRY Participants Group (North America). Antibacterial activity of 41 antimicrobials tested against over 2773 bacterial isolates from hospitalized patients with pneumoniae, I: Results from the SENTRY Antimicrobial Surveillance Program (North America, 1998).  Diagn Microbiol Infect Dis . 2001;  39 105-116
• 24 The SENTRY Participants Group (Latin America), Lewis M T, Gales A C, Sader H S, Pfaller M A, Jones R N. Frequency of occurrence and antimicrobial susceptibility patterns for pathogens isolated from Latin American patients with a diagnosis of pneumonia: results from the SENTRY Antimicrobial Surveillance Program (1998).  Diagn Microbiol Infect Dis . 2000;  37 63-74
• 25 Kirby J T, Mutnick A H, Jones R N, Biedenbach D J, Pfaller M A, and the SENTRY Participants Group. Geographic variations in garenoxacin (BMS284756) activity tested against pathogens associated with skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (2000).  Diagn Microbiol Infect Dis . 2002;  43 303-309
• 26 Mathai D, Jones R N, Pfaller M A, and the SENTRY Participant Group (North America). Epidemiology and frequency of resistance among pathogens causing urinary tract infections in 1510 hospitalized patients: a report from the SENTRY Antimicrobial Surveillance Program (North America).  Diagn Microbiol Infect Dis . 2001;  40 129-136
• 27 Jones R N, Kugler K C, Pfaller M A, Winokur P L, and the SENTRY Surveillance Group (North America). Characteristics of pathogens causing urinary tract infections in hospitals in North America: results from the SENTRY Antimicrobial Surveillance Program, 1997.  Diagn Microbiol Infect Dis . 1999;  35 55-63
• 28 Gales A C, Gordon K A, Wilke W W, Pfaller M A, Jones R N. Occurrence of single-point gyr A mutations among ciprofloxacin-susceptible Escherichia coli isolates causing urinary tract infections in Latin America.  Diagn Microbiol Infect Dis . 2000;  36 61-64
• 29 Jones R N, Beach M L, Pfaller M A. Spectrum and activity of three contemporary fluoroquinolones tested against Pseudomonas aeruginosa isolates from urinary tract infections in the SENTRY Antimicrobial Surveillance Program (Europe and the Americas, 2000): More alike than different! Diagn Microbiol Infect Dis .  2001;  41 161-163
• 30 Stephen J, Mutnick A, Jones R N. Assessment of pathogens and resistance (R) patterns among intensive care unit (ICU) patients in North America (NA): initial report from the SENTRY Antimicrobial Surveillance Program (2001)Abstract C2-297. In: Programs and Abstracts of the 42nd Interscience Congress of Antimicrobial Agents and Chemotherapy American Society for Microbiology, San Diego, CA. 2002
• 31 Garcia-Rodriguez J-A, Jones R N, and the MYSTIC Programme Study Group. Antimicrobial resistance in gram-negative isolates from European intensive care units: data from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme.  J Chemother . 2002;  14 25-32
• 32 CDC NNIS System. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1990-May 1999, issued June 1999.  Am J Infect Control . 1999;  27 520-532
• 33 Centers for Disease Control and Prevention. Update: Staphylococcus aureus with reduced susceptibility to vancomycin.  United States, 1997. Morb Mortal Wkly Rep . 1997;  46 813-815
• 34 Hiramatsu K, Aritaka N, Hanaki H, Kawasaki S, Hosoda Y, Hori S. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin.  Lancet . 1997;  350 70-73
• 35 Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover F C. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.  J Antimicrob Chemother . 1997;  40 135-146
• 36 Centers for Disease Control. Staphylococcus aureus resistant to vancomycin.  United States, 2002. Morb Mortal Wkly Rep . 2002;  51 565-567
• 37 Tsiodras S, Godl H S, Sakoulas G. Linezolid resistance in a clinical isolate of Staphylococcus aureus Lancet .  2001;  358 207-208
• 38 Mutnick A, Jones R N, Rhomberg P, Moet G. Oxazolidinone (OXA)-resistant (R) enterococci emerging in 2001; report patients from the SENTRY Antimicrobial Surveillance Program (USA) [abstract C2-288]. In: Programs and Abstracts of the 42nd Interscience Congress of Antimicrobial Agents and Chemotherapy American Society for Microbiology, San Diego, CA. 2002
• 39 Malbruny B, Canu A, Bozdogan B. Resistance to quinupristin/dalfopristin due to mutation of L22 ribosomal protein in Staphylococcus aureus Antimicrob Agents Chemother .  2002;  46 2200-2207
• 40 Deshpande L M, Fix A M, Pfaller M A, the SENTRY Antimicrobial Surveillance Program Participants Group, Jones R N. Emerging elevated mupirocin resistance rates among staphylococcal isolates in the SENTRY Antimicrobial Surveillance Program (2000): correlations of results from disk diffusion, Etest and reference dilution methods.  Diagn Microbiol Infect Dis . 2002;  42 283-290
• 41 Rhomberg P, Jones R N, Mutnick A. Geographic variations and trends in key bacteremic pathogen resistance (R): report from the SENTRY Antimicrobial Surveillance Program (1997-2001) [abstract C2-298]. In: Programs and Abstracts of the 42nd Interscience Congress of Antimicrobial Agents and Chemotherapy American Society for Microbiology, San Diego, CA 2002
• 42 Ike Y, Arakawa Y, Ma X. Nationwide survey shows that methicillin-resistant Staphylococcus aureus strains heterogeneously and intermediately resistant to vancomycin are not disseminated throughout Japanese hospitals.  J Clin Microbiol . 2001;  39 4445-4451
• 43 Schwalbe R S, Stapleton J T, Gilligan P H. Emergence of vancomycin resistance in coagulase-negative staphylococci.  N Engl J Med . 1987;  316 927-931
• 44 Diekema D J, Jones R N. Oxazolidinone antibiotics.  Lancet . 2001;  358 1975-1982
• 45 Mutnick A H, Biedenbach D J, Turnidge J D, Jones R N. Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998-2000.  Diagn Microbiol Infect Dis . 2002;  43 65-73
• 46 Gonzales R D, Schreckenberger P C, Graham M G, Kelkar S, Den-Besten K, Quinn J P. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid.  Lancet . 2001;  357 1179-1182
• 47 Jones R N, Della-Latta P H, Lee L V, Biedenbach D J. Linezolid-resistant Enterococcus faecium isolated from a patient without prior exposure to an oxazolidinone: report from the SENTRY Antimicrobial Surveillance Program.  Diagn Microbiol Infect Dis . 2002;  42 137-139
• 48 Huycke M M, Sahm D F, Gilmore M S. Multiple-drug resistant enterococci: the nature of the problem and an agenda for the future.  Emerg Infect Dis . 1998;  4 239-249
• 49 Centers for Disease Control. Nosocomial enterococci resistant to vancomycin: United States, 1989-1993; National Nosocomial Infections Surveillance.  Morb Mortal Wkly Rep . 1993;  42 597-599
• 50 Low D E, Keller N, Barth A, Jones R N. Clinical prevalence, antimicrobial susceptibility, and geographic resistance patterns of enterococci: results from the SENTRY Antimicrobial Surveillance Program, 1997-1999.  Clin Infect Dis . 2001;  32(suppl 2) S133-S145
• 51 Carmeli Y, Eliopoulos G M, Samore M H. Antecedent treatment with different antibiotic agents as a risk factor for vancomycin-resistant Enterococcus Emerg Infect Dis .  2002;  8 802-804
• 52 Mallon D JP, Corkill J E, Hazel S M. Excretion of vancomycin-resistant enterococci by wild mammals.  Emerg Infect Dis . 2002;  8 636-638
• 53 Hoban D J, Doern G V, Fluit A C, Roussel-Delvallez M, Jones R N. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999.  Clin Infect Dis . 2001;  32(suppl 2) S81-S93
• 54 Jones R N, Pfaller M A. Macrolide and fluoroquinolone (levofloxacin) resistances among Streptococcus pneumoniae strains: significant trends from the SENTRY Antimicrobial Surveillance Program (North America, 1997-1999).  J Clin Microbiol . 20002;  38 4298-4299
• 55 Roson B, Carratala J, Tubau F. Usefulness of β-lactam therapy for community-acquired pneumonia in the era of drug-resistant Streptococcus pneumoniae: a randomized study of amoxicillin/clavulanic and ceftriaxone.  Microb Drug Resist . 2001;  7 85-96
• 56 Jones R N, Pfaller M A. Letter to the Editor. Potencies of newer fluoroquinolones against viridans group streptococci isolated in 637 cases of blood stream infection in the SENTRY Antimicrobial Surveillance Program (1997 to 1999): beyond Canada! Antimicrob Agents Chemother .  2000;  44 2922-2923
• 57 Gordon K A, Beach M L, Biedenbach D J, Jones R N, Rhomberg P R, Mutnick A H. Antimicrobial susceptibility patterns of β-haemolytic and viridans group streptococci: report from the SENTRY Antimicrobial Surveillance Program (1997-2000).  Diagn Microbiol Infect Dis . 2002;  43 157-162
• 58 Winokur P L, Canton R, Casellas J-M, Legakis N. Variations in the prevalence of strains expressing an extended-spectrum β-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region.  Clin Infect Dis . 2001;  32(suppl 2) S94-S103
• 59 Jones R N, Baquero F, Privitera G, Inoue M, Wiedemann B. Inducible β-lactamase-mediated resistance to third-generation cephalosporins.  Clin Microbiol Infect . 1997;  3(suppl 1) S7-S20
• 60 Jones R N, Varnam D J. Antimicrobial activity of broad-spectrum agents tested against gram-negative bacilli resistant to ceftazidime: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001).  Diagn Microbiol Infect Dis . 2002;  44 379-382
• 61 Gales A C, Jones R N, Turnidge J, Rennie R, Ramphal R. Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999.  Clin Infect Dis . 2001;  32(suppl 2) S146-S155
• 62 Jones R N, Pfaller M A. Ciprofloxacin as broad-spectrum empiric therapy: are fluoroquinolones still viable monotherapeutic agents compared with β-lactams: data from the MYSTIC Program (US)?.  Diagn Microbiol Infect Dis . 2002;  42 213-215
• 63 Evans M E, Feola D J, Rapp R P. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria.  Ann Pharmacother . 1999;  33 960-967
• 64 Gales A C, Reis A O, Jones R N. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines.  J Clin Microbiol . 2001;  39 183-190
• 65 Burns J L, Saiman L, Whittier S. Comparison of agar diffusion methodologies for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients.  J Clin Microbiol . 2000;  38 1818-1822
• 66 Burns J L, Saiman L, Whittier S. Comparison of two commercial systems (Vitek and MicroScan-WalkAway) for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients.  Diagn Microbiol Infect Dis . 2001;  39 257-260
• 67 Gales A C, Jones R N, Forward K R, Linares J, Sader H S, Verhoef J. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999).  Clin Infect Dis . 2001;  32(suppl 2) S104-S113
• 68 Wisplinghoff H, Edmond M B, Pfaller M A, Jones R N, Wenzel R P, Seifert H. Nosocomial blood stream infections caused by Acinetobacter species in United States hospitals: clinical features, molecular epidemiology, and antimicrobial susceptibility.  Clin Infect Dis . 2000;  31 690-697
• 69 Jellison T K, McKinnon P S, Rybak M J. Epidemiology, resistance, and outcomes of Acinetobacter baumannii bacteremia treated with imipenem-cilastatin or ampicillin/sulbactam.  Pharmacother . 2001;  21 142-148
• 70 Page M I. Understanding metallo-β-lactamases.  ASM News . 2002;  68 217-221
• 71 Livermore D M, Woodford N. Carbapenems: a problem in waiting?.  Curr Opin Microbiol . 2000;  3 489-495
• 72 Nordmann P, Poirel L. Emerging carbapenemases in gram-negative aerobes.  Clin Microbiol Infect . 2002;  8 321-331
• 73 Gales A C, Biedenbach D J, Winokur P, Hacek D M, Pfaller M A, Jones R N. Carbapenem-resistant Serratia marcescens isolated producing Bush Group 2f β-lactamase (SME-1) in the United States: results from the MYSTIC Programme.  Diagn Microbiol Infect Dis . 2001;  39 125-127
• 74 Kollef M H, Ward S, Sherman G. Inadequate treatment of nosocomial infections is associated with certain empiric antibiotic choices.  Critical Care Med . 2000;  28 3458-3464
• 75 Ambrose P G, Grasela D M. The use of Monte Carlo simulation to examine the pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae Diagn Microbiol Infect Dis .  2000;  38 151-157
• 76 Ambrose P G, Owens Jr C R, Garvey M J, Jones R N. Pharmacodynamic considerations in the treatment of moderate to severe pseudomonal infections with cefepime.  J Antimicrob Chemother . 2002;  49 445-453
• 77 Ambrose P G, Owens R C, Grasela D M. Antimicrobial pharmacodynamics.  Med Clin N Am . 2000;  84 1431-1445
• 78 Ambrose P G, Richerson M A, Stanton M E. Cost-effective analysis of cefepime compared with ceftazidime in intensive care unit patients with hospital-acquired pneumoniae.  Infect Dis Clin Pract . 1999;  8 245-251
• 79 Kuti J L, Nightingale C H, Quintiliani R, Nicolau D P. Pharmacodynamic profiling of continuously infused piperacillin/tazobactam against Pseudomonas aeruginosa using Monte Carlo analysis.  Diagn Microbiol Infect Dis . 2002;  44 51-57